452092-31-8

Basic information

• Product Name: 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester
• Synonyms: 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester;ethyl 1-cyclopropyl-6,7-difluoro-8 -hydroxy-4-oxo-1,4-dihydroquinoline-3 -carboxylate;Moxifloxacin Impurity 9;Moxifloxacin impurity R;Moxifloxacin Impruty 26;1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl;Moxifloxacin Impurity N
• CAS NO: 452092-31-8
• Molecular Formula: C₁₅H₁₃F₂NO₄
• Molecular Weight: 309.2648264
• Product Categories: Aromatics, MIscellaneous Reagents
• Mol File: 452092-31-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 457.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.523±0.06 g/cm3(Predicted)
• PKA: 5.75±0.20(Predicted)
• CAS DataBase Reference: 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester(452092-31-8)
• EPA Substance Registry System: 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester(452092-31-8)

Safety Data

• Hazardous Substances Data: 452092-31-8(Hazardous Substances Data)

Usage

Uses

1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester is used in the synthesis of antibacterials.

Upstream product

• 154093-72-8 1-cyclopropyl-6,7-difluoro-8-hydroxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 64-17-5 ethanol 
• 112811-71-9 ethyl 8-methoxy-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate 
• 452092-34-1 8-benzyloxy-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 

Downstream Products

• 1194056-72-8 ethyl 8-(3-((2R,4R)-1-(benzyloxycarbonyl)-4-(4-methoxybenzyloxy)pyrrolidin-2-yl)prop-1-ynyl)-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1194058-81-5 ethyl 8-[(4S)-4-{[(benzyloxy)carbonyl]amino}-7-tert-butoxy-7-oxohept-1-yn-1-yl]-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1194057-65-2 ethyl 7-((2S,4R)-4-benzyloxycarbonylamino-2-(hydroxymethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-hydroxymethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1194057-67-4 ethyl (3aS,5R)-5-benzyloxycarbonylamino-13-cyclopropyl-8-fluoro-10-oxo-3a,4,5,6,10,13-hexahydro-1H,3H-pyrrolo[2',1':3,4][1,4]oxazepino[5,6-h]quinoline-11-carboxylate 
• 1194057-64-1 ethyl 7-((2S,4R)-4-benzyloxycarbonylamino-2-(hydroxymethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-fomyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1029429-55-7 8-((S)-1-benzyl-4-methylene-piperidin-2-ylmethoxy)-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 128426-94-8 ethyl 1-cyclopropyl-6,7-difluoro-8-difluoromethoxyl-1,4-dihydro-4-oxo quinoline-3-carboxylate 
• 1194056-57-9 ethyl 8-(2-((2S,4R)-1-(benzyloxycarbonyl)-4-(tert-butyldimethylsilyloxy)pyrrolidin-2-yl)ethoxy)-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 

Relevant articles and documents

Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones

Conformationally constrained tetracyclic fluoroquinolones (FQs) were synthesized and profiled for their microbiological spectrum. The installation of a seven-membered ring between the pyrrolidine substituents and the C8 position on the FQ core scaffold resulted in a remarkable enhancement of microbiological potency toward both Gram-positive and Gram-negative bacteria. Focused optimization of seven-membered ring composition, stereochemistry, and amine placement led to the discovery of the two lead compounds that were selected for further progression.

5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS

The invention relates to novel chimeric antibiotics of formula (I) wherein R1 represents OH, OPO3H2 or OCOR5; R2 represents H, OH or OPO3H2; R3 represents H or halogen

NOVEL ANTIBACTERIAL COMPOUNDS

The invention relates to novel chimeric antibiotics of formula (I) Wherein R1 is CH2NHCOR5, heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl; R2 is H, OH, OSO3H, OPO3H2, OCH2OPO3H2, OCOCH2CH2COOH, OCOR6; R3 is H or halogen; R4 is (C1-C3)alkyl, (C1-C3)haloalkyl or cycloalkyl; R5 is alkyl or haloalkyl; and R6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).